SRZNW (Surrozen) Current Ratio: 11.91 (As of Mar. 2026) — 36% Above Median


SRZNW Surrozen Inc SRZNW
27 GF Score
Price $0.02
! 8 Warning Signs
View Full Analysis

What is Surrozen Current Ratio?

Surrozen SRZNW 27 Current Ratio is 11.91 as of Mar. 2026, which is 36% above its 10-year median of 8.77. GuruFocus rates SRZNW with a GF Score™ of 27/100. The stock has 8 warning signs investors should review. Among 1,411 Biotechnology companies, Surrozen ranks better than 81.79% on this metric.

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Surrozen's current ratio for the quarter that ended in Mar. 2026 was 11.91.

Surrozen has a current ratio of 11.91. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Surrozen's Current Ratio or its related term are showing as below:

SRZNW' s Current Ratio Range Over the Past 10 Years
Min: 5.18   Med: 8.77   Max: 16.41
Current: 11.91

During the past 6 years, Surrozen's highest Current Ratio was 16.41. The lowest was 5.18. And the median was 8.77.

SRZNW's Current Ratio is ranked better than
81.79% of 1411 companies
in the Biotechnology industry
Industry Median: 3.91 vs SRZNW: 11.91

Surrozen  (NAS:SRZNW) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Surrozen Current Ratio Related Terms


Surrozen Current Ratio Historical Data

* Premium members only.

The historical data trend for Surrozen's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surrozen Current Ratio Chart

Surrozen Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Ratio
Get a 7-Day Free Trial 7.75 8.35 5.75 5.32 9.22

Surrozen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.02 16.41 13.15 9.22 11.91

SRZNW vs SABS, GLSI, ZNTL: Current Ratio Comparison

For the Biotechnology subindustry, Surrozen's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surrozen Current Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Surrozen's Current Ratio distribution charts can be found below:

* The bar in red indicates where Surrozen's Current Ratio falls into.


SRZNW
27GF Score
Surrozen Inc SRZNW
Current Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Surrozen Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Surrozen's Current Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Current Ratio (A: Dec. 2025 )=Total Current Assets (A: Dec. 2025 )/Total Current Liabilities (A: Dec. 2025 )
=91.559/9.93
=9.22

Surrozen's Current Ratio for the quarter that ended in Mar. 2026 is calculated as

Current Ratio (Q: Mar. 2026 )=Total Current Assets (Q: Mar. 2026 )/Total Current Liabilities (Q: Mar. 2026 )
=113.949/9.565
=11.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Current Ratio →
What does a Current Ratio of 11.91 mean?
Surrozen (SRZNW) has a Current Ratio of 11.91 as of Mar. 2026. This is 36% above median its historical median of 8.77. Over the past decade, Surrozen's Current Ratio has ranged from 5.18 to 16.41. According to the industry distribution chart, Surrozen ranks #257 out of 1411 companies in the Biotechnology industry, placing it in the top 18.2%.
Is Surrozen's Current Ratio too high?
Surrozen's current Current Ratio of 11.91 is 36% above median its 10-year median of 8.77. Over the past 10 years, this metric has ranged from a low of 5.18 to a high of 16.41. The Biotechnology industry median Current Ratio is 3.91. Surrozen's value of 11.91 is 204.6% above this industry median. Based on the distribution chart, Surrozen ranks #257 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Surrozen has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Surrozen's Current Ratio compare to SABS and GLSI?
According to the Biotechnology industry distribution chart, Surrozen ranks #257 out of 1411 companies for Current Ratio. This places Surrozen in the top 18% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.91. Surrozen's value of 11.91 is 204.6% above this benchmark. Historically, Surrozen's own Current Ratio has ranged from 5.18 to 16.41 over the past decade. While the company's 10-year median is 8.77 vs. the industry median of 3.91, Surrozen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.91, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surrozen's current Current Ratio of 11.91 is 204.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surrozen's current Current Ratio is 11.91, which is 36% above median its own 10-year median of 8.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surrozen stock overvalued right now?
Surrozen (SRZNW) has a current Current Ratio of 11.91. The current Current Ratio is 11.91, which is 36% above median its 10-year median of 8.77 and 204.6% above the Biotechnology industry median of 3.91. Surrozen's overall GF Score™ is 27/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Surrozen (SRZNW), the current Current Ratio is 11.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Surrozen Business Description

Other Exchanges SRZN:USA
Address 171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
27GF Score

Get the complete analysis for SRZNW

Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price